Article Sidebar
Published:
Aug 19, 2023DOI:
10.4314/tjpr.v22i7.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of capecitabine and melatonin on HER2+ (SK-BR-3) and HER2- (MCF7) human breast cancer cell lines
Abstract
Purpose: To determine the effect of melatonin in combination with capecitabine on the proliferation and induction of apoptosis in MCF-7 and SK-BR-3 breast cancer cell lines.
Methods: The MTT assay (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) was performed to investigate the effect of capecitabine and in combination with melatonin on cell lines and to determine the half-maximal concentration (IC50) and combination index. Expression of apoptotic markers, Bax, Bcl-2, and caspase-3 were measured by polymerase chain reaction (PCR) after treatment.
Results: The IC50 of melatonin and capecitabine in MCF-7 and SK-BR-3 cell lines were 4.52 mM and 619.36 μg/mL, and 5.1 mM and 679.51 μg/mL, respectively. The combined use of melatonin and capecitabine significantly reduced IC50. Also, combination index (CI) values were < 1, indicating that the combination of capecitabine and melatonin has a synergistic effect. The results of gene expression also showed enhancement in the Bax/Bcl-2 ratio in melatonin-capecitabine combination compared with capecitabine alone in both cell lines.
Conclusion: Melatonin-capecitabine-induced cell death is controlled by caspase-3 and Bax/Bcl-2-dependent apoptosis. The combination of melatonin and capecitabine has a synergistic effect on both HER2+ and HER2- cells.
